Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2016-11-09 Earnings Release
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2016, by Zafgen, Inc. It announces the company's financial results for the third quarter of 2016 and includes a press release as an exhibit. The text explicitly states it is a current report pursuant to the Securities Exchange Act of 1934 and contains a press release with financial results highlights. The document is relatively short (2887 characters) and serves as an announcement of quarterly financial results rather than a full detailed report. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only. Therefore, the correct classification is ER with high confidence.
2016-11-09 English
FORM 4 SUBMISSION
Director's Dealing
2016-08-31 English
FORM 10-Q
Interim / Quarterly Report Q2 2016
2016-08-04 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 4, 2016, by Zafgen, Inc. It announces the company's financial results for the second quarter of 2016 and includes a press release as Exhibit 99.1. The text explicitly states that the press release is being furnished and incorporated by reference, and the document itself is a current report rather than a full financial report. The length is 2865 characters, which is relatively short and consistent with an earnings release announcement rather than a full quarterly report. The key phrase 'announced its financial results for the second quarter' and the inclusion of a press release as an exhibit strongly indicate this is an Earnings Release (ER). It is not a full Interim/Quarterly Report (IR) because it lacks substantive financial statements or detailed analysis, and it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains the actual announcement of results, not just a notice of report availability.
2016-08-04 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-08-02 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-08-01 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.